CVE:MDP

Medexus Pharmaceuticals Stock Forecast, Price & News

C$7.75

-0.40 (-4.91 %)

(As of 06/16/2021)

Add

Compare

Today's Range

C$7.70

▼

C$8.14

50-Day Range

C$7.28

▼

C$8.15

52-Week Range

C$2.80

▼

C$9.75

Volume40,981 shs

Average Volume68,619 shs

Market CapitalizationC$148.54 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive MDP News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.

MEDEXUS PHARMACEUTICALS INC (MDP.TO) stock forecast and price target
July 7, 2021 | finance.yahoo.com

Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch
June 10, 2021 | ca.finance.yahoo.com

Medexus Announces Availability of Triamcinolone Hexacetonide in the United States
June 9, 2021 | ca.finance.yahoo.com

Medexus to Present at the Sidoti & Company Virtual Microcap Conference on May 19th
May 12, 2021 | markets.businessinsider.com

Medexus Pharmaceuticals Inc. Wt
March 31, 2021 | wsj.com

Medexus Pharmaceuticals shares climb as Canaccord Genuity upgrades rating to Buy from Hold following fiscal 3Q results
March 3, 2021 | proactiveinvestors.com

Medexus Pharmaceuticals shares rise after fiscal 3Q results earn repeat Speculative Buy rating, C$9 target from Mackie
March 2, 2021 | proactiveinvestors.com

Medexus Pharmaceuticals reveals record quarterly revenue of C$31.5M
March 2, 2021 | proactiveinvestors.com

Medexus begins selling tumor imaging powder Gleolan in Canadian full commercial launch
February 26, 2021 | proactiveinvestors.com

Medexus forms licensing agreement with German pharma company to commercialize treosulfan in the US
February 3, 2021 | proactiveinvestors.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange CVE
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolCVE:MDP
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.medexus.com
Phone514-762-2626
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual SalesC$108.29 million
Price / Sales1.37
Cash FlowC$0.62 per share
Price / Cash Flow12.46
Book ValueC$0.38 per share
Price / Book20.50

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares19,167,000
Market CapC$148.54 million
Next Earnings Date8/9/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.83 out of 5 stars

2.5 Analyst's Opinion

Consensus Rating
Medexus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$9.00, Medexus Pharmaceuticals has a forecasted upside of 16.1% from its current price of C$7.75.
Amount of Analyst Coverage
Medexus Pharmaceuticals has received no research coverage in the past 90 days.

5.0 Community Rank

Outperform Votes
Medexus Pharmaceuticals has received 18 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Medexus Pharmaceuticals has received 6 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Medexus Pharmaceuticals has received 75.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Medexus Pharmaceuticals and other stocks. Vote “Outperform” if you believe MDP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Medexus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Medexus Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Medexus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$23,915.00 in company stock and sold C$0.00 in company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Medexus Pharmaceuticals is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Medexus Pharmaceuticals is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Due to a projected decrease in earnings for Medexus Pharmaceuticals, their PEG ratio cannot be calculated.
Price to Book Value per Share Ratio
Medexus Pharmaceuticals has a P/B Ratio of 20.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Medexus Pharmaceuticals (CVE:MDP) Frequently Asked Questions

Is Medexus Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medexus Pharmaceuticals stock.
View analyst ratings for Medexus Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Medexus Pharmaceuticals?

Wall Street analysts have given Medexus Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medexus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Medexus Pharmaceuticals' next earnings date?

Medexus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Medexus Pharmaceuticals.

How has Medexus Pharmaceuticals' stock been impacted by COVID-19?

Medexus Pharmaceuticals' stock was trading at C$3.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MDP stock has increased by 158.3% and is now trading at C$7.75.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MDP?

2 brokerages have issued 1-year target prices for Medexus Pharmaceuticals' stock. Their forecasts range from C$9.00 to C$9.00. On average, they expect Medexus Pharmaceuticals' stock price to reach C$9.00 in the next year. This suggests a possible upside of 16.1% from the stock's current price.
View analysts' price targets for Medexus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Medexus Pharmaceuticals' key executives?

Medexus Pharmaceuticals' management team includes the following people:

Mr. Kenneth d'Entremont, CEO & Director
Mr. Roland Boivin, Chief Financial Officer
Mr. Bill Poncy, Sr. VP of Commercial Operations - United States
Mr. Brian Peters, VP of Sales & Marketing - United States
Ms. Tina Byers CFA, Exec. of Investor Relations
Mr. Michael Pine, Sr. VP of Bus. Devel. & Strategy
Mr. Michael David Adelman, Gen. Mang., U.S. Operations (Age 50)

Who are some of Medexus Pharmaceuticals' key competitors?

Some companies that are related to Medexus Pharmaceuticals include HLS Therapeutics (HLS), Benchmark (BMK), Amryt Pharma (AMYT), The Supreme Cannabis (FIRE), ESSA Pharma (EPI), Leaf Mobile (LEAF), ICC Labs (ICC), The Green Organic Dutchman (TGOD), Venture Life Group (VLG), Science in Sport (SIS), Diurnal Group (DNL), BioSyent (RX), Shield Therapeutics (STX), Delta 9 Cannabis (NINE) and The Flowr (FLWR).
View all of MDP's competitors.

What other stocks do shareholders of Medexus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medexus Pharmaceuticals investors own include Gatekeeper Systems (GSI), Enghouse Systems (ENGH), (ATE) and Ag Growth International (AFN).

What is Medexus Pharmaceuticals' stock symbol?

Medexus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MDP."

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Medexus Pharmaceuticals' stock price today?

One share of MDP stock can currently be purchased for approximately C$7.75.

How much money does Medexus Pharmaceuticals make?

Medexus Pharmaceuticals has a market capitalization of C$148.54 million and generates C$108.29 million in revenue each year.

What is Medexus Pharmaceuticals' official website?

The official website for Medexus Pharmaceuticals is www.medexus.com.

How can I contact Medexus Pharmaceuticals?

The company can be reached via phone at 514-762-2626.

This page was last updated on 8/2/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here